Fusion Pharmaceuticals Inc (FUSN)

Etorro trading 970x250
Fusion Pharmaceuticals Inc (FUSN) Logo

About Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada. Address: 270 Longwood Road South, Hamilton, ON, Canada, L8P 0A6

Fusion Pharmaceuticals Inc News and around…

Latest news about Fusion Pharmaceuticals Inc (FUSN) common stock and company :

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies
20 Oct, 2021 Yahoo! Finance

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies (TATs) at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labell

Analysts Expect BIB To Hit $114
08 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $114.26 per unit.

Fusion Pharmaceuticals is Now Oversold (FUSN)
05 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer
28 Sep, 2021 Yahoo! Finance

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Mohit Rawat as President and Chief Business Officer. Mr. Rawat brings to Fusion more than 15 years of experience in the biopharmaceutical industry, with expertise in corporate strategy, business development and commercial execution, including product development, launch planning and commercialization.

Fusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
23 Sep, 2021 Yahoo! Finance

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 2:40pm ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business Development
21 Sep, 2021 Yahoo! Finance

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development.

5 Value Stocks In The Healthcare Sector
06 Sep, 2021 FinancialContent

What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same ...

Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences
02 Sep, 2021 Yahoo! Finance

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming virtual investor conferences.

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Aug, 2021 Yahoo! Finance

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 80,000 shares of its common stock to one employee outside Fusion's 2020 Stock Option and Incentive Plan. The stock options were granted as an inducement material to the individual becoming an employe

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021
26 Aug, 2021 FinancialContent

Upgrades Scotiabank upgraded the previous rating for Enerplus Corp (NYSE:ERF) from Sector Perform to Sector Outperform. ...

Grab This Bargain Even Cheaper Than Director Gannon Did
24 Aug, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on August 19, Fusion Pharmaceuticals Inc's Director, Steven Gannon, invested $25,526.55 into 3,171 shares of FUSN, for a cost per share of $8.05..

We Think Fusion Pharmaceuticals (NASDAQ:FUSN) Can Afford To Drive Business Growth
23 Aug, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production
12 Aug, 2021 Yahoo! Finance

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have righ

Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Update
10 Aug, 2021 Yahoo! Finance

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the second quarter ended June 30, 2021 and provided an update on clinical and corporate developments.

Fusion Pharmaceuticals to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference
05 Aug, 2021 Yahoo! Finance

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Hot Topic - Radiopharmaceuticals" panel discussion at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 4:05pm EDT. Participating in the panel on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

12 Health Care Stocks Moving In Friday's Pre-Market Session
30 Jul, 2021 FinancialContent

Gainers Erytech Pharma (NASDAQ:ERYP) shares moved upwards by 79.56% to $7.38 during Friday's pre-market session. The ...

44 Stocks Moving In Thursday's Mid-Day Session
29 Jul, 2021 FinancialContent

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 47.6% to $2.8198 after the company announced it received registration ...

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
29 Jul, 2021 FinancialContent

Gainers Cocrystal Pharma (NASDAQ:COCP) stock moved upwards by 30.9% to $1.44 during Thursday's pre-market session. ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
29 Jul, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're kicking off another busy day of trading with a dive into the biggest pre-market stock movers for Thursday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now.

28 Stocks Moving in Thursday's Pre-Market Session
29 Jul, 2021 FinancialContent

Gainers LendingClub Corporation (NYSE: LC) shares rose 44.6% to $23.49 in pre-market trading after the company reported ...

Fusion Pharma Stock Is Trading Higher As FDA Clears Early-Stage Study For Radiopharmaceutical In Neck, Bladder Cancers
29 Jul, 2021 FinancialContent

TheFDA has signed offFusion Pharmaceuticals Inc's(NASDAQ: FUSN) Investigational New Drug (IND) applications for ...

10 Stocks Moving In Wednesday's After-Hours Session
28 Jul, 2021 FinancialContent

Gainers Qualcomm (NASDAQ: QCOM) shares are trading higher after the company reported better-than-expected Q3 EPS and sales results ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
28 Jul, 2021 FinancialContent

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock rose 11.46% to $2.43 during Wednesday's after-market session. Trading volume for ...

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3
28 Jul, 2021 Yahoo! Finance

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) applications for [225Ac]-FPI-1966 (FPI-1966) and imaging agent [111In]-FPI-1967 (FPI-1967). FPI-1966 is a targeted alpha therapy (TAT) designed to use vofatamab, a human monoclonal antibody, to target and deliver acti

Analysts Forecast 25% Gains Ahead For The Holdings of IBBQ
15 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $31.33 per unit.

5 Stocks To Watch For July 6, 2021
06 Jul, 2021 FinancialContent

Some of the stocks that may grab investor focus today are: Wall Street expects Smart Global Holdings Inc (NASDAQ: SGH) to post ...

12 Health Care Stocks Moving In Thursday's After-Market Session
17 Jun, 2021 FinancialContent

Gainers Midatech Pharma (NASDAQ:MTP) shares moved upwards by 6.44% to $3.14 during Thursday's after-market session. Today's trading ...

48 Biggest Movers From Yesterday
17 Jun, 2021 FinancialContent

Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
16 Jun, 2021 FinancialContent

Gainers Orphazyme (NASDAQ:ORPH) shares moved upwards by 72.49% to $17.34 during Wednesday's regular session. As of ...

Fusion Pharmaceuticals Inc (FUSN) is a NASDAQ Common Stock listed in , ,

970x250